Dare Bioscience announced the completion of its registered direct offering of common stock and warrants to purchase common stock priced at-the-market under Nasdaq rules with an institutional investor and an investor affiliated with the licensor of one of the company’s early stage product candidates. The aggregate gross proceeds to Dare, before deducting offering expenses payable by Dare, were $7.0 million. The closing occurred on September 1, 2023. Dare’s completed equity financing included minority participation by an investor affiliated with Douglas.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DARE:
- Dare Bioscience to sell 10M shares at 70c in registered direct offering
- Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Dare Bioscience announces 2H of 2023 anticipated developments
- Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
- Dare Bioscience reports Q2 EPS (10c), consensus (10c)